Qube Research & Technologies (QRT)
CRVS icon

Qube Research & Technologies (QRT)’s Corvus Pharmaceuticals CRVS Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-33,228
Closed -$486K – 3557
2026
Q1 		$486K Sell
33,228
-81,272
-71% -$1.3M ﹤0.01% 2744
2025
Q4 		$882K Buy
+114,500
New +$903K ﹤0.01% 2602
2025
Q3 		– Sell
-43,969
Closed -$176K – 3635
2025
Q2 		$176K Sell
43,969
-405,111
-90% -$1.47M ﹤0.01% 2936
2025
Q1 		$1.43M Sell
449,080
-970
-0.2% -$4.57K ﹤0.01% 2107
2024
Q4 		$2.41M Buy
450,050
+322,718
+253% +$2.41M ﹤0.01% 1805
2024
Q3 		$672K Buy
+127,332
New +$457K ﹤0.01% 2175
2024
Q2 		– Sell
-2,378
Closed -$4.23K – 3943
2024
Q1 		$4.23K Buy
+2,378
New +$4.97K ﹤0.01% 3914
2020
Q4 		– Sell
-61,724
Closed -$248K – 1869
2020
Q3 		$248K Buy
61,724
+50,083
+430% +$200K ﹤0.01% 1318
2020
Q2 		$32K Buy
+11,641
New +$34.4K ﹤0.01% 1642

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Qube Research & Technologies (QRT)'s CRVS Position: Q2 2026 in Review

Qube Research & Technologies (QRT) sold out of Corvus Pharmaceuticals (CRVS) in Q2 2026, closing a stake of 33,228 shares — an estimated $486K sold.

Qube Research & Technologies (QRT) first reported a position in CRVS in Q2 2020 and held it in 9 quarters. The position peaked at $2.41M in Q4 2024. 173 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Qube Research & Technologies (QRT) reported no remaining Corvus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 33,228 Corvus Pharmaceuticals shares in Q2 2026, an estimated $486K.
  • Qube Research & Technologies (QRT) first reported a position in Corvus Pharmaceuticals in Q2 2020 and held it in 9 quarters.
  • Qube Research & Technologies (QRT)'s Corvus Pharmaceuticals position peaked at $2.41M in Q4 2024.
  • 173 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.